Welcome to our dedicated page for Camp4 Therapeutics news (Ticker: CAMP), a resource for investors and traders seeking the latest updates and insights on Camp4 Therapeutics stock.
CAMP4 Therapeutics Corporation reports developments as a clinical-stage biopharmaceutical company developing regulatory RNA-targeting therapeutics designed to upregulate gene expression and restore healthy protein levels in genetic diseases. Company updates center on its RAP Platform, regRNA mapping, antisense oligonucleotide candidates and CMP-002 for SYNGAP1-related disorder, along with regulatory submissions, orphan-drug designation and natural-history research collaborations.
Recurring news also includes financial results, research and development spending, financing activity, business-development agreements such as the GSK collaboration, board and governance changes, inducement equity grants under Nasdaq rules and investor conference participation.
CalAmp (Nasdaq: CAMP) appointed Nathan Lowstuter as the new Senior Vice President of Global Supply Chain and Operations. With over 20 years of experience in supply chain management and operations, Lowstuter will enhance CalAmp's efficiency and product delivery. His previous role at Proterra Inc. involved developing supply chain strategies that supported significant business growth. Lowstuter holds an MBA from the University of Southern California and is a certified Six Sigma Black Belt. This appointment aims to streamline operations as CalAmp scales its global presence.